MedTrace Logo

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

NCT00345501 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2007-08-24

No results posted yet for this study

Summary

The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing CMN in high-risk patients undergoing a coronary procedure.

Conditions

  • Renal Insufficiency, Chronic
  • Coronary Angiography
  • Angioplasty, Transluminal, Percutaneous Coronary

Interventions

DRUG

Iloprost

Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end

DRUG

Placebo

Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end

Sponsors & Collaborators

  • Onassis Cardiac Surgery Centre

    lead OTHER

Principal Investigators

  • Konstantinos Spargias, MD · Onassis Cardiac Surgery Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2007-07-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00345501 on ClinicalTrials.gov